Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
1.
Vet Surg ; 42(4): 448-54, 2013 May.
Article in English | MEDLINE | ID: mdl-23574511

ABSTRACT

OBJECTIVES: To compare the pharmacodynamics of once daily and twice daily administration of low molecular weight heparin (LMWH) administration in horses. STUDY DESIGN: Randomized cross over study. ANIMALS: Adult mixed breed healthy mares (n = 6). METHODS: LMWH (dalteparin) was administered (50 U/kg subcutaneously) either every 12 or 24 hours for 3 consecutive days. Anti-factor Xa activity was measured before and at select time points after LMWH administration. Packed cell volume (PCV), platelet count, partial thromboplastin time (PTT), and anti-thrombin (AT) activity were monitored throughout the study. RESULTS: No changes in PCV, platelet count, or AT activity were detected with either frequency of daily LMWH administration. Values for PTT increased throughout the study but never exceeded the normal reference interval. Anti-factor Xa activity was maintained within or above the suggested thromboprophylactic range (0.1-0.2 U/mL) when LMWH was administered twice daily, but fell below this range ≈ 16 hours after administration when given once daily. For both once and twice daily LMWH administration, the area under the curve was significantly greater after the last dose of LMWH when compared to the first dose. CONCLUSIONS: Administration of LMWH once or twice daily for 3 consecutive days appears to be safe in healthy adult horses. Anti-factor Xa activity was maintained within or above the suggested thromboprophylactic range for 24 hours with twice daily LMWH administration but not with once daily administration.


Subject(s)
Anticoagulants/pharmacology , Dalteparin/pharmacology , Horses/blood , Animals , Anticoagulants/adverse effects , Anticoagulants/blood , Blood Coagulation/drug effects , Dalteparin/adverse effects , Dalteparin/blood , Female
2.
Int J Clin Pharmacol Ther ; 51(6): 482-9, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23587152

ABSTRACT

OBJECTIVE: The aim of this study was to develop a novel population pharmacokinetic (PPK) model of dalteparin after subcutaneous (s.c.) injection, to describe the impact of the "flip-flop" phenomenon and to demonstrate any ethnic difference between Asian and Caucasian subjects. MATERIALS AND METHODS: The PPK model was constructed based on data collected from Asian (Japanese) and Caucasian (French) subjects with a total of 931 plasma anti-Xa activity measurements. After s.c. injection, the apparent elimination half-life of the dalteparin was about 4 hours, longer than that reported after intravenous (i.v.) injection, indicating a "flip-flop" phenomenon. In addition, following the mono-exponential decline profile after s.c. injection, a longer secondary phase was apparently observed in 70% of subjects. To investigate the phenomenon, we applied a dual absorption model including fast first-order and slow zero-order inputs as the structural model. RESULTS: The PPK model for s.c. injection provided the half-life consistent with that of i.v. injection and could account for the observed bi-phasic profile. Body weight and gender for clearance and body weight for volume of distribution were identified as covariates. Due to lower body weight in Asian subjects, an ethnic difference might occur but it would not be reflected by per kg body weight injection. CONCLUSIONS: Dalteparin PK profiles after s.c. injection were described reasonably by the novel PPK model based on flip-flop pharmacokinetics and a dual absorption process.


Subject(s)
Anticoagulants/pharmacokinetics , Dalteparin/pharmacokinetics , Factor Xa Inhibitors , Models, Biological , Absorption , Adult , Anticoagulants/administration & dosage , Anticoagulants/blood , Anticoagulants/pharmacology , Asian People , Body Weight , Cross-Over Studies , Dalteparin/administration & dosage , Dalteparin/blood , Dalteparin/pharmacology , Female , Half-Life , Humans , Injections, Subcutaneous , Male , Metabolic Clearance Rate , Middle Aged , Molecular Weight , Single-Blind Method , Time Factors , White People , Young Adult
3.
Clin Exp Pharmacol Physiol ; 38(11): 783-6, 2011 Nov.
Article in English | MEDLINE | ID: mdl-21883380

ABSTRACT

1. The low molecular weight heparin (LMWH) dalteparin is used, for example, to prevent primary venous thromboembolism in patients undergoing surgery or in medically ill patients. The anticoagulant activity of dalteparin can be monitored by measuring anti-factor Xa levels and activated partial thromboplastin time (aPTT); however, aPTT is an unreliable parameter in this case. The aim of the present in vitro study was to evaluate the thrombelastograph ROTEM(®) (Tem International, Munich, Germany) with respect to determining the anticoagulant activity of dalteparin at therapeutic and supratherapeutic plasma concentrations. 2. The ROTEM(®) parameters, namely coagulation time (CT), clot formation time (CFT) and maximum clot firmness (MCF), were measured using the reagents EXTEM and INTEM (Pentapharm, Munich, Germany) at increasing concentrations of dalteparin (0.01-10 µg/mL, which corresponded to anti-factor Xa levels of 1-1000 U/mL, respectively). 3. The mean CT measured using EXTEM was found to increase from 65.4 ± 27.9 s at baseline to 173.3 ± 112.2 s and 332.2 ± 200.7 s at drug concentrations of 1 and 10 µg/mL, respectively (P < 0.0001 for both). Moreover, the mean CFT value (EXTEM) increased from 97.7 ± 21.5 s at baseline to 187.6 ± 115.2 s (P = 0.0001) at a drug concentration of 10 µg/mL, which is greater than the therapeutic anti-factor Xa concentrations for LMWH. The results obtained when INTEM was used as the reagent were similar to those obtained using EXTEM. 4. In conclusion, the results indicate that the thrombelastograph ROTEM(®) can detect the anticoagulant effects of dalteparin only at supratherapeutic levels of anti-factor Xa.


Subject(s)
Anticoagulants/therapeutic use , Dalteparin/therapeutic use , Factor Xa Inhibitors , Heparin, Low-Molecular-Weight/therapeutic use , Thrombelastography/methods , Adult , Anticoagulants/blood , Blood Coagulation/drug effects , Blood Coagulation Tests/methods , Blood Platelets/drug effects , Dalteparin/blood , Dose-Response Relationship, Drug , Factor Xa/metabolism , Germany , Humans , Male , Partial Thromboplastin Time/methods
4.
Perfusion ; 25(4): 191-6, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20530518

ABSTRACT

OBJECTIVES: Sonoclot was used in this study to monitor low molecular weight heparin (LMWH) during haemodialysis. MATERIAL AND METHODS: Two different intravenous doses (standard / half-dose) of dalteparin were studied in eight patients. Blood was sampled for coagulation analyses with Sonoclot, thrombin-antithrombin (TAT) and anti-Xa. A visual fibrin deposition score (VFS) in the venous drip chamber was also evaluated. RESULTS: All patients completed their dialysis. There was a progressive increase in TAT levels, which correlated to the dalteparin dose. Significant differences (p<0.05) were found for TAT, VFS and Sonoclot celite-activated clotting time (SonACT) between the different LMWH dosages. TAT and Sonoclot correlated to each other, but not to the VFS. SonACT was significantly increased at two hours, with the high dalteparin dose compared to the lower dose. CONCLUSION: Both Sonoclot and TAT failed to predict the VFS. No patient had any clinical clotting events and all dialyses were completed successfully.


Subject(s)
Anticoagulants/blood , Dalteparin/blood , Kidney Failure, Chronic/therapy , Renal Dialysis/methods , Aged , Anticoagulants/administration & dosage , Antithrombins/analysis , Blood Coagulation/drug effects , Blood Coagulation Tests/instrumentation , Cross-Over Studies , Dalteparin/administration & dosage , Drug Monitoring/methods , Female , Humans , Kidney Failure, Chronic/blood , Male , Middle Aged , Thrombelastography , Thrombin/analysis
5.
Thromb Haemost ; 96(6): 750-5, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17139369

ABSTRACT

Low-molecular-weight heparins undergo renal elimination, and therefore the proper dosing in hemodialysis (HD) patients is unclear. It was the objective of this study to evaluate the pharmacokinetic (PK) parameters of dalteparin in patients receiving chronic HD for end-stage renal disease. We performed a multidose PK study with prophylactic doses of dalteparin in twelve HD patients. Dalteparin 5,000 IU was administered subcutaneously daily for four consecutive days, with HD performed on day 2 and day 4. Anti-factor Xa activity was determined daily and at multiple blood samples after the 3rd and 4th dose. Eleven of 12 patients completed the study. The mean (range) PK parameters determined after the 4th dose were as follows: i) maximum concentration (Cmax ) was 0.31 IU/ml (0.06 to 0.55 IU/ml); ii) time to Cmax was 3.55 hours (2.59 to 4.96 hr); iii) area under the curve was 3.24 IU*hr/ml (0.64 to 6.44 IU*hr/ml); iv) half-life was 3.82 hr (2.03 to 9.63 hr); and v) trough anti-factor Xa activity 0.04 IU/ml (0.02 to 0.08 IU/ml). No major bleeding was observed. In general, patients with lower body weight exhibited a higher Cmax . From this pilot PK study, we have determined initial PK parameters for dalteparin in HD patients. Although a standard prophylactic dose was used, we found that in this patient population differences in body weight influenced the Cmax. Future studies to evaluate the PK parameters of dalteparin in patients receiving chronic HD may have to use weight-based dosing and will need to be performed over a longer period of time.


Subject(s)
Anticoagulants/pharmacokinetics , Dalteparin/pharmacokinetics , Kidney Failure, Chronic/metabolism , Renal Dialysis , Adult , Aged , Aged, 80 and over , Anticoagulants/administration & dosage , Anticoagulants/blood , Anticoagulants/pharmacology , Area Under Curve , Body Weight , Dalteparin/administration & dosage , Dalteparin/blood , Dalteparin/pharmacology , Drug Administration Schedule , Drug Monitoring , Factor Xa Inhibitors , Female , Humans , Injections, Subcutaneous , Kidney Failure, Chronic/therapy , Male , Middle Aged , Pilot Projects
6.
Int J Clin Pharmacol Ther ; 44(10): 455-65, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17063975

ABSTRACT

The pharmacokinetics of the low-molecular weight heparin (LMWH), dalteparin, was evaluated after a single intravenous bolus injection of 50 IU anti-Xa/kg in 8 healthy volunteers, 8 patients with moderate/severe renal failure (Cl(crea) 13.1-56.5 ml/min) and 8 hemodialysis patients. Venous blood samples were taken over a 1-day period to determine anti-Xa activity, anti-IIa activity and plasma levels of free tissue factor pathway inhibitor (free TFPI). Plasma anti-Xa and anti-IIa activities were measured using chromogenic assays and free TFPI levels using an ELISA technique. The anti-Xa clearance was significantly decreased (p < 0.05) in both groups with renal insufficiency when compared with healthy volunteers. There was a positive correlation between creatinine clearance and anti-Xa clearance in the healthy volunteers and patients with moderate/severe renal failure. The anti-Ila activity was characterized by 3- to 4-fold lower plasma concentrations and faster elimination compared with the anti-Xa activity. In patients with moderate/severe renal failure the elimination of anti-lla was only slightly decreased, whereas in hemodialysis patients anti-Ila clearance was significantly decreased (p < 0.01). There was no correlation between creatinine clearance and anti-IIa clearance. The baseline mean free TFPI plasma levels in the two groups with renal insufficiency were significantly higher (p < 0.01) than in healthy volunteers. Dalteparin administration induced a transient, 6.0- to 8.1-fold increase in the free TFPI values in the three study groups. Dalteparin induced an increase in C(max) and AUC(0 - infinity) values of free TFPI in the two groups with renal insufficiency that was higher than in healthy volunteers. No bleeding complications occurred during the study. In conclusion, this is the first report showing retarded elimination of dalteparin and enhanced free TFPI plasma levels induced by a LMWH in patients with renal insufficiency.


Subject(s)
Anticoagulants/pharmacokinetics , Dalteparin/pharmacokinetics , Renal Insufficiency/metabolism , Adolescent , Adult , Anticoagulants/blood , Creatinine/urine , Dalteparin/blood , Factor Xa/metabolism , Factor Xa Inhibitors , Female , Humans , Lipoproteins/blood , Male , Metabolic Clearance Rate , Middle Aged , Prothrombin/antagonists & inhibitors , Prothrombin/metabolism , Reference Values , Renal Dialysis , Renal Insufficiency/blood , Renal Insufficiency/therapy , Renal Insufficiency/urine , Severity of Illness Index
7.
Am J Obstet Gynecol ; 191(3): 1024-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15467584

ABSTRACT

OBJECTIVE: The purpose of this study was to determine whether standard therapeutic doses of dalteparin maintain peak therapeutic levels of anticoagulation during pregnancy. STUDY DESIGN: This was a prospective trial in which 13 pregnancies that required therapeutic anticoagulation were treated with dalteparin 100 U/kg every 12 hours; peak and trough (predose) low molecular weight heparin (anti-Xa activity) levels were monitored every 2 weeks. Dosage adjustments were made to maintain peak anti-Xa activity between 0.5 and 1.0 IU/ml. Bone density and bone turnover markers were measured. RESULTS: A total of 250 peak and trough low-molecular-weight heparin (LMWH) levels were obtained. Eighty-five percent of pregnancies (11/13) required an upward dosage adjustment. Trough levels were in the therapeutic range only 9% of the time, despite the maintenance of therapeutic peak levels. Bone resorption markers and density were unchanged in singleton pregnancies. CONCLUSION: Dalteparin dosing, based on weight alone, every 12 hours is inadequate to maintain most pregnant women in the therapeutic range throughout pregnancy as measured by anti-Xa activity. Trough levels are rarely in the therapeutic range, despite maintenance of therapeutic peak levels. These notable changes in low molecular weight heparin peak may explain reported failures in pregnancy.


Subject(s)
Anticoagulants/administration & dosage , Dalteparin/administration & dosage , Pregnancy Complications, Cardiovascular/drug therapy , Venous Thrombosis/drug therapy , Abortion, Spontaneous/epidemiology , Adult , Dalteparin/blood , Dose-Response Relationship, Drug , Female , Heparin, Low-Molecular-Weight/administration & dosage , Heparin, Low-Molecular-Weight/blood , Humans , Pregnancy , Pregnancy Outcome , Prospective Studies
8.
Thromb Haemost ; 88(1): 37-40, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12152674

ABSTRACT

In patients who receive co-administered low-molecular-weight heparin (LMWH) and continuous epidural analgesia (CEA) after orthopedic surgery, there is concern about an increased risk of a spinal epidural hematoma. The practice of twice-daily LMWH dosing in North America might, in part, account for the greater number of epidural hematomas reports compared to Europe where once-daily LMWH is used. We performed a prospective cohort study in patients who had orthopedic surgery and received co-administered LMWH and CEA. We investigated the trough anticoagulant effect, as measured by an anti-Xa heparin level, at the time of epidural catheter removal in patients who received twice-daily or once-daily LMWH. Twenty-five patients who received enoxaparin, 30 mg twice-daily, and 25 patients who received dalteparin, 5,000 IU once-daily, had anti-Xa heparin levels measured on the second or third post-operative day at the time of epidural catheter removal. In patients who received twice-daily enoxaparin, or once-daily dalteparin, the anti-Xa heparin level was measured, on average, 10.4 h and 21.8 h, respectively, after the preceding LWMH dose. All 25 patients who received once-daily LMWH had an anti-Xa heparin level < 0.10 U/ml at the time of catheter removal. Of 25 patients who received twice-daily LMWH, the anti-Xa heparin level at the time of catheter removal was > or = 0.20 U/ml in 5 patients (P = 0.050), and > or = 0.10 U/ml in 7 patients (P = 0.009). We conclude that in patients who are receiving co-administered LMWH and CEA after orthopedic surgery, twice-daily but not once-daily LMWH administration is more likely to be associated with a clinically important anticoagulant effect at the time of epidural catheter removal.


Subject(s)
Analgesia, Epidural/methods , Factor X/antagonists & inhibitors , Heparin, Low-Molecular-Weight/administration & dosage , Orthopedic Procedures , Aged , Catheters, Indwelling , Cohort Studies , Dalteparin/administration & dosage , Dalteparin/blood , Drug Therapy, Combination , Enoxaparin/administration & dosage , Enoxaparin/blood , Female , Hematoma, Epidural, Cranial/chemically induced , Heparin, Low-Molecular-Weight/blood , Humans , Male , Middle Aged , Postoperative Care , Prospective Studies
9.
Am J Vet Res ; 63(6): 868-73, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12061534

ABSTRACT

OBJECTIVE: To determine pharmacokinetic variables and to evaluate the influence on clotting times after SC administration of single doses of dalteparin and enoxaparin to horses. ANIMALS: 5 healthy adult horses. PROCEDURES: The study was designed as a 4-period crossover study. Each horse received a single SC injection of dalteparin (50 and 100 anti-Xa U/kg) and enoxaparin (40 and 80 anti-Xa U/kg). Plasma anti-Xa activities and clotting times were measured, and pharmacokinetic variables were determined. Absolute and relative maximal prolongation of clotting times was calculated, and correlation between plasma anti-Xa activities and clotting times was determined. RESULTS: The SC administration of each of the doses of the 2 preparations was well tolerated. Time course of the anti-Xa activities could be described in a 1-compartment model. Comparison of low- and high-dose treatments revealed a disproportionate increase of the area under the plasma activity-time curve and prolongation of the terminal half-life, but the increase in maximum plasma activity was proportionate, and peak plasma concentrations corresponded with concentrations recommended in human medicine. There were only mild changes in activated partial thromboplastin time (aPTT), whereas the influence on thrombin time (TT) was greater, dose-dependent, and more variable. A weak-to-moderate correlation between aPTT and plasma anti-Xa activities and a moderate-to-strong correlation between TT and plasma anti-Xa activities were found. CONCLUSIONS AND CLINICAL RELEVANCE: Pharmacokinetic and anticoagulatory properties of low-molecular-weight heparins in horses are similar to those found in humans. Once-daily SC administration of dalteparin or enoxaparin may be useful as an anticoagulatory treatment in horses.


Subject(s)
Anticoagulants/pharmacology , Dalteparin/pharmacokinetics , Enoxaparin/pharmacokinetics , Horses/metabolism , Animals , Anticoagulants/administration & dosage , Anticoagulants/blood , Area Under Curve , Cross-Over Studies , Dalteparin/administration & dosage , Dalteparin/blood , Enoxaparin/administration & dosage , Enoxaparin/blood , Female , Half-Life , Injections, Subcutaneous/veterinary , Male , Partial Thromboplastin Time/veterinary , Thrombin Time/veterinary
10.
J Am Coll Cardiol ; 39(5): 811-7, 2002 Mar 06.
Article in English | MEDLINE | ID: mdl-11869846

ABSTRACT

OBJECTIVES: This study compared rebound coagulation in patients with acute coronary syndrome patients after discontinuation of unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH). BACKGROUND: Up to a quarter of patients hospitalized for unstable angina experience recurrent ischemia after discontinuation of UFH or LMWH therapy, which may be the result of rebound coagulation activation and subsequent thrombosis. It is unknown whether UFH and LMWH differ in this respect. METHODS: We randomized 71 patients admitted with unstable angina to intravenous UFH or subcutaneous LMWH (dalteparin) and measured plasma markers of coagulation before, during, and after treatment. RESULTS: A complete series of measurements was obtained in 59 patients. Plasma prothrombin fragment 1+2 (F(1+2)) levels decreased in both groups during treatment. After loss of therapeutic plasma drug levels, F(1+2) increased (within 3 h) to a maximum level at 12 to 24 h that was higher than before or during treatment in both groups (p < 0.0001). In both groups, F(1+2) levels remained higher than pretreatment up to 24 h after discontinuation. Similarly, thrombin-antithrombin (TAT) levels exceeded treatment and pretreatment levels, at a slower rate after dalteparin than after UFH. However, after dalteparin a higher peak value of TAT was observed. CONCLUSIONS: Rebound coagulation activation occurs within hours after discontinuation of both UFH and dalteparin. With both drugs, thrombin generation is significantly greater after treatment than before or during treatment. A longer duration or weaning of treatment, or continuation with another anticoagulant treatment, may reduce rebound coagulation activation and ischemic events.


Subject(s)
Angina, Unstable/drug therapy , Anticoagulants/therapeutic use , Coronary Thrombosis/prevention & control , Dalteparin/therapeutic use , Heparin, Low-Molecular-Weight/therapeutic use , Heparin/therapeutic use , Withholding Treatment , Angina, Unstable/blood , Angina, Unstable/physiopathology , Anticoagulants/blood , Coronary Thrombosis/blood , Coronary Thrombosis/physiopathology , Dalteparin/blood , Female , Fibrinolysis/drug effects , Fibrinolysis/physiology , Heparin/blood , Heparin, Low-Molecular-Weight/blood , Humans , Male , Middle Aged , Recurrence , Thrombin/drug effects , Thrombin/physiology , Time Factors
11.
Br J Plast Surg ; 54(7): 597-603, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11583496

ABSTRACT

Coagulation and fibrinolysis activities in relation to trauma, surgery and thrombosed microanastomoses were studied during free-flap surgery in eight patients with lower-extremity defects due to recent trauma or chronic ulcers. One patient had an intraoperative thrombosis, and three more patients required reoperations on the same day due to postoperative thromboses; one of these also required a second reoperation due to flap failure. The baseline level of fibrinogen was slightly elevated in all patients except one, and was significantly higher in the patients who underwent reoperation. At the end of the primary surgery, distinct thrombin generation (TAT and F1+2) was seen in three patients with excessive bleeding, and all three later underwent reoperations. One of these patients generated excessive thrombin on the eighth postoperative day, upon removal of a necrotic flap. Thrombin generation (F1+2) was also seen at baseline in the patient with the intraoperative thrombosis, and persisted on the first postoperative day. D-dimer at baseline was higher in patients with recent trauma, and in two of these, both of whom underwent reoperations on the same day, D-dimer remained high perioperatively. Resistance to fibrinolysis with increased PAI-1 levels was seen in these two patients at the time of reoperation. In all, TAT and F1+2 were associated with the threat of flap failure. A preoperative hypercoagulable state and excessive bleeding during the operation were predictors of reoperation. The markers for coagulation and fibrinolysis could be used preoperatively to target antithrombotic control, and postoperatively to detect the threat of flap failure. Meticulous haemostasis during surgery might help to diminish the need for reoperations.


Subject(s)
Fibrinolysis/physiology , Microsurgery/adverse effects , Surgical Flaps/physiology , Thrombosis/physiopathology , Adult , Aged , Analysis of Variance , Blood Coagulation/physiology , C-Reactive Protein/analysis , Dalteparin/blood , Enzyme-Linked Immunosorbent Assay , Female , Fibrin Fibrinogen Degradation Products/analysis , Fibrinogen/analysis , Heparin, Low-Molecular-Weight/therapeutic use , Humans , Male , Microsurgery/methods , Middle Aged , Plasminogen Activator Inhibitor 1/blood , Reoperation , Statistics, Nonparametric , Surgical Flaps/blood supply , Thrombin/analysis , Thrombosis/blood , Thrombosis/drug therapy , Treatment Outcome
12.
Blood Coagul Fibrinolysis ; 12(2): 149-55, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11302478

ABSTRACT

A history of thromboembolism is associated with an increased risk of new thromboembolic events during pregnancy. Prophylaxis with heparin during pregnancy implicates long-term treatment with daily injections with either unfractionated heparin (UFH) or low molecular mass heparin (LMMH). Prolonged treatment with heparin may result in endothelial absorption and drug accumulation. In order to test this hypothesis, anti-FXa activity during pregnancy was measured in four women allergic to conventional UFH, who were treated with LMMH (dalteparin; Pharmacia). It was found that, at the commencement of treatment, it took more than 8 days to reach a steady maximum peak value, located 3 h after the given dose. One daily dosage of 5,000 IU anti-Xa resulted in a measurable level of FXa for 24 h in pregnancy week 40, compared with 17h at pregnancy week 37. The implications of an elevated anti-FXa activity during pregnancy, especially during the third trimester and at partus, are discussed. We present a reduced dose regime near term and during delivery.


Subject(s)
Anticoagulants/blood , Anticoagulants/therapeutic use , Dalteparin/blood , Dalteparin/therapeutic use , Pregnancy Complications, Cardiovascular/prevention & control , Thromboembolism/prevention & control , Adult , Anticoagulants/administration & dosage , Dalteparin/administration & dosage , Factor Xa Inhibitors , Female , Gestational Age , Heparin/adverse effects , Humans , Pregnancy , Urticaria/chemically induced , Venous Thrombosis/drug therapy
13.
Blood Coagul Fibrinolysis ; 11(4): 395-400, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10847428

ABSTRACT

The effect of plasmapheresis on the anticoagulant properties of the low molecular weight heparins has never been studied. We had the opportunity to study this effect in a woman who was receiving dalteparin for the treatment of a pulmonary embolus and required plasmapheresis. Over the course of 8 days, five courses of plasmapheresis were performed. Anti-Xa activity was measured pre- and post-dalteparin administration both during and between the first three courses of plasmapheresis. Comparing the rate of change between pairs of anti-Xa activity, the absorption rate was found to have decreased by over 50%. The decay rate, as compared with a historical control, was found to have increased by over 480%. These results suggest that the level of anticoagulation of dalteparin, as monitored through an anti-Xa assay, is reduced by plasmapheresis.


Subject(s)
Anemia, Hemolytic/blood , Anemia, Hemolytic/therapy , Dalteparin/blood , Fibrinolytic Agents/blood , Plasmapheresis , Aged , Dalteparin/therapeutic use , Female , Fibrinolytic Agents/therapeutic use , Humans
14.
Berl Munch Tierarztl Wochenschr ; 113(3): 103-7, 2000 Mar.
Article in German | MEDLINE | ID: mdl-10763553

ABSTRACT

The pharmacokinetics of a low molecular weight heparin (LMWH; Fragmin D) was studied in dogs after intravenous and subcutaneous administration, based on antifactor Xa- (anti-fXa-) activity. Each dosage was examined in 5 adult Beagles. After intravenous application of 25, 50 and 100 anti-fXaU./kg body weight (BW) the mean peak plasma heparin activity of 0.52 +/- 0.12 (x +/- s), 1.08 +/- 0.23 and 1.86 +/- 0.17 anti-fXaU./ml, respectively, was measured. After subcutaneous application of 50, 100 and 200 anti-fXaU./kg BW maximum heparin activity in the plasma was determined after 144-216 minutes (mean values) of 0.28 +/- 0.01, 0.52 +/- 0.06 or 1.09 +/- 0.20 anti-fXaU./ml. Intravenous application of LMWH has a short plasma terminal half-life (t50) between 49 and 76 minutes which depended on the dosage. After administration of 50 anti-fXaU./kg BW (74 minutes) and 100 anti-fXaU./kg BW (76 minutes) no essential difference was shown. A distinctly longer t50 was found after subcutaneous injection. After injection of 50, 100 and 200 anti-fXaU./kg BW t50 values of 81, 123 and 182 minutes were calculated. According to this, with increasing dosage a decrease of the total clearance was found for both application routes. The apparent volume of distribution after intravenously applicated LMWH ranged between 50 and 70 ml/kg BW. The absolute bioavailability calculated for the subcutaneous NMH-injection of 50 and 100 anti-fXaU./kg BW was 107% and 104%, respectively.


Subject(s)
Dalteparin/pharmacokinetics , Animals , Dalteparin/administration & dosage , Dalteparin/blood , Dogs , Half-Life , Infusions, Intravenous , Injections, Subcutaneous
15.
Haemostasis ; 30(5): 225-32, 2000.
Article in English | MEDLINE | ID: mdl-11251329

ABSTRACT

INTRODUCTION: We had previously shown that the use of bile salts, which act as surfactants, facilitates the intestinal absorption of large molecules such as those of heparin and insulin. However, the bioavailability of unfractionated heparin (UFH) administered through the large intestine was low. The aim of the present study was to evaluate the absorption of low molecular weight heparin (LMWH) combined with bile salts through the gut mucosa in animals and human subjects. MATERIALS AND METHODS: LMWH (Fragmin, Kabi-Pharmacia, Stockholm) or UFH with or without sodium cholate (Sch) was administrated rectally in rats and healthy volunteers via a microenema. Absorption was estimated by the activated partial thromboplastin time (aPTT), the plasma anti-factor Xa activity and the plasma lipoprotein lipase (LPL) activation. RESULTS: In groups of 6 rats, LMWH at doses of 100--1,000 U with sodium cholate (10--20 mg/ml) was readily absorbed through the gut mucosa, as indicated by both, anti-factor Xa levels of up to 1 U/ml and a dose-dependent activation of LPL. The absorption was significantly superior to that of UFH with Sch or LMWH given without Sch (p < 0.001). The plasma anti-factor Xa levels in the 6 healthy volunteers who received a microenema containing 25,000 U of LMWH with 20 mg/ml of Sch were 0.38 U/ml at 15 min and 0.1 U/ml at 240 min. LPL activation and aPTT prolongation were also observed in these subjects. The plasma LMWH levels after rectal application were in the same range as those obtained after subcutaneous administration, however the elimination time (t 1/2) was shorter. There were no adverse reactions. CONCLUSIONS: Intestinal absorption of LMWH facilitated by Sch is both feasible and safe. A slow release formulation will be needed to prolong the plasma half-life.


Subject(s)
Heparin, Low-Molecular-Weight/pharmacokinetics , Intestinal Absorption/drug effects , Administration, Rectal , Adult , Animals , Anticoagulants/administration & dosage , Anticoagulants/blood , Anticoagulants/pharmacokinetics , Bile Acids and Salts/administration & dosage , Bile Acids and Salts/pharmacology , Biological Availability , Dalteparin/administration & dosage , Dalteparin/blood , Dalteparin/pharmacokinetics , Dose-Response Relationship, Drug , Drug Combinations , Enzyme Activation/drug effects , Factor Xa Inhibitors , Female , Heparin, Low-Molecular-Weight/administration & dosage , Heparin, Low-Molecular-Weight/blood , Humans , Intestinal Mucosa/metabolism , Lipoprotein Lipase/metabolism , Male , Rats , Sodium Cholate/administration & dosage , Sodium Cholate/pharmacology
16.
Blood Coagul Fibrinolysis ; 9(4): 343-50, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9690805

ABSTRACT

Seventeen women with previously verified thromboembolism were included in a pharmacokinetic evaluation of dalteparin during the third trimester of pregnancy. The bioavailability of morning subcutaneous administration of dalteparin (crossover study) was also compared with that in the evening. Fifteen women injected themselves subcutaneously with 5000 IU and two with 2500 IU dalteparin once daily. An anti-FXa activity of 0.20-0.40 IU/ml 3 h after injection was obtained. The means +/- SD, when comparing morning and evening doses for 5000 IU, were: Cmax 0.21 +/- 0.05 and 0.20 +/- 0.05 IU anti-FXa/ml, AUC 0-24 h 1.97 +/- 0.46 and 1.93 +/- 0.55 IU x h/ml and tmax 3.71 +/- 0.89 and 4.32 +/- 1.60 h, respectively (NS). The two regimens were equivalent. A measurable anticoagulant effect was still observed 16 h after injection of 5000 IU dalteparin. The half-lives after a morning and an evening dose of 5000 IU dalteparin were 4.92 +/- 2.80 and 3.87 +/- 1.15 h, respectively (NS). There were no changes in thrombin marker levels during the two pharmacokinetic measurements.


Subject(s)
Anticoagulants/pharmacokinetics , Dalteparin/pharmacokinetics , Pregnancy Trimester, Third/metabolism , Adult , Anticoagulants/administration & dosage , Anticoagulants/blood , Antithrombin III/analysis , Area Under Curve , Circadian Rhythm , Cross-Over Studies , Dalteparin/administration & dosage , Dalteparin/blood , Dose-Response Relationship, Drug , Factor Xa/analysis , Factor Xa Inhibitors , Female , Fibrin/analysis , Fibrin Fibrinogen Degradation Products/analysis , Half-Life , Humans , Peptide Fragments/analysis , Peptide Hydrolases/analysis , Pregnancy , Prothrombin/analysis , Therapeutic Equivalency , Thrombosis/prevention & control , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...